Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Harvard Bioscience (HBIO) over the last 16 years, with Q4 2024 value amounting to $43.5 million.

  • Harvard Bioscience's Shares Outstanding (Weighted Average) rose 263.55% to $43.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $43.5 million, marking a year-over-year increase of 263.55%. This contributed to the annual value of $43.5 million for FY2024, which is 263.55% up from last year.
  • Latest data reveals that Harvard Bioscience reported Shares Outstanding (Weighted Average) of $43.5 million as of Q4 2024, which was up 263.55% from $42.4 million recorded in Q4 2023.
  • Harvard Bioscience's Shares Outstanding (Weighted Average)'s 5-year high stood at $43.5 million during Q4 2024, with a 5-year trough of $38.3 million in Q1 2020.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $40.2 million (2021), whereas its average is $40.3 million.
  • Per our database at Business Quant, Harvard Bioscience's Shares Outstanding (Weighted Average) skyrocketed by 181.78% in 2020 and then soared by 471.22% in 2021.
  • Harvard Bioscience's Shares Outstanding (Weighted Average) (Quarter) stood at $38.6 million in 2020, then increased by 4.41% to $40.3 million in 2021, then grew by 2.65% to $41.4 million in 2022, then rose by 2.43% to $42.4 million in 2023, then rose by 2.64% to $43.5 million in 2024.
  • Its last three reported values are $43.5 million in Q4 2024, $42.4 million for Q4 2023, and $41.4 million during Q4 2022.